Traumatic Brain Injury – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Traumatic Brain Injury – Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
- The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects
- The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abalonex LLCAegisCN LLC
AivoCode LLP
Algernon Pharmaceuticals Inc
AlphaCognition Inc
ALSP Inc
AlzeCure Pharma AB
American CryoStem Corp
Amgen Inc
Anagin Inc
Anida Pharma Inc
Annovis Bio Inc
AntiRadical Therapeutics LLC
Argenica Therapeutics Ltd
ArunA Bio Inc
Asha Therapeutics LLC
Astrocyte Pharmaceuticals Inc
Athersys Inc
B Cell Solutions Inc
Bessor Pharma LLC
Beth Israel Deaconess Medical Center
Beyond Barriers Therapeutics Inc
BioIncept LLC
Biosplice Therapeutics Inc
Bioxytran Inc
Brain-Gen LLC
Braxia Scientific Corp
Caladria Therapeutics Inc
CalciMedica Inc
Calico Life Sciences LLC
CavoGene LifeSciences
Cellvation Inc
CereSpir Inc
Chrysalis BioTherapeutics Inc
Claritas Pharmaceuticals Inc
Cognosci Inc
Complement Pharma BV
Covis Pharmaceuticals Inc
DeckTherapeutics Inc
Deha Pharmaceutical LLC
DermaXon LLC
Drexel University
Eikonoklastes Therapeutics Inc
Eisai Co Ltd
Elicio Therapeutics Inc
Encue LLC
Epigen Biosciences Inc
EuMentis Therapeutics Inc
Eustralis Pharmaceuticals Ltd
Fortuna Fix Inc
GABA Therapeutics Inc
GNT Pharma Co Ltd
Gryphon Bio Inc
Hemarina SA
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Hope Biosciences LLC
Hopstem Biotechnology LLC
Hoth Therapeutics Inc
Hoverink Biotechnologies Inc
Ilios Therapeutics Inc
ImmunoChem Therapeutics LLC
Incannex Healthcare Ltd
Inflammatory Response Research Inc
Institute of Biotechnology and Pharmaceutical Research
International Stem Cell Corp
Ischemix Inc
JT Pharmaceuticals Inc
Jupiter Neurosciences Inc
Levolta Pharmaceuticals Inc
Lucy Scientific Discovery Inc
M et P Pharma AG
Mapreg SAS
Medicortex Finland Oy
Mercaptor Discoveries Inc
Mitochon Pharmaceuticals Inc
NervGen Pharma Corp
NeuExcell Therapeutics Inc
NeurAegis Inc
NeurExo Sciences LLC
Neurodon LLC
Neuronasal LLC
NeuroNascent Inc
Neuropathix Inc
Neuroplast BV
NeuroTau Inc
NeuroTheranostics Inc
NeuroTrauma Sciences LLC
New World Laboratories Inc
NoNO Inc
Noveome Biotherapeutics Inc
Nura Bio Inc
NuvOx Pharma LLC
Nyrada Inc
Odyssey Health Inc
Okayama University
Orpheris Inc
Owl Therapeutics LLC
Oxeia Biopharmaceuticals Inc
Peptron Inc
Personalized Stem Cells Inc
PharmaTher Holdings Ltd
PharmatrophiX Inc
Praetego Inc
ProNeurogen Inc
ProThera Biologics Inc
Protheragen Inc
PurMinds NeuroPharma Inc
Qrons Inc
RegeneRx Biopharmaceuticals Inc
Resolys Bio Inc
Revalesio Corp
RHNanopharmacuticals LLC
Rubicon Biotechnology Inc
Rutgers The State University of New Jersey
Salk Institute for Biological Studies
Samus Therapeutics Inc
SanBio Co Ltd
SciSparc Ltd
Shinkei Therapeutics LLC
Sihuan Pharmaceutical Holdings Group Ltd
Silver Creek Pharmaceuticals Inc
SL Bigen Co Ltd
Spinogenix Inc
STATegics Inc
Stemedica Cell Technologies Inc
Stream Biomedical Inc
Symbinas Pharmaceuticals Inc
Synaptogenix Inc
Takeda Pharmaceutical Co Ltd
Tetra Therapeutics
The University of New South Wales press Limited
Thera Neuropharma Inc
Therapeutic Solutions International Inc
Theratome Bio Inc
TikoMed AB
UAB Minority Health and Health Equity Research Center
University of Manitoba
Verinos Pharmaceuticals GmbH
Virogenomics BioDevelopment Inc
Vitro Biopharma Inc
Vitti Labs LLC
Vivazome Therapeutics Pty Ltd
ZyVersa Therapeutics Inc